20/20 Biolabs is trading 10.4% down at $0.28, as broader inflation concerns weigh on risk sentiment.
- No company-specific announcement explaining the October 15 decline surfaced; the latest listed company event was its participation in the Maxim Growth Summit on October 14.
- September producer prices rose 1.3% month over month, while core PPI increased 0.7%, above the 0.3% expectation. The hotter reading intensified rate concerns and pressured risk-sensitive shares.